Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

33.3%

2 terminated out of 6 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 2 (2)
P 3 (1)

Trial Status

Terminated2
Recruiting2
Enrolling By Invitation1
Unknown1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07444957Recruiting

Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease

NCT06657326Not ApplicableRecruiting

LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients

NCT06763549Enrolling By Invitation

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT02131142Phase 2Unknown

BioFreedom US IDE Feasibility Trial

NCT00944333Phase 3Terminated

Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy

NCT00157001Phase 2Terminated

Feasibility Study of Photopheresis Post Angioplasty

Showing all 6 trials

Research Network

Activity Timeline